Cell And Gene Therapy Manufacturing

  1. Collaborating with the FDA: Dr. Peter Marks and Dr. Nicole Verdun Share Advice For Small And Emerging Biotechs 1/30/2024

    In this segment, Dr. Peter Marks and Dr. Nicole Verdun share their advice and best practices for small and emerging biotechs when working with the FDA.

  2. Simplify Your Process Of Choosing An Optimal Resin 5/19/2025

    Discover how to address evolving biotherapeutic purification challenges with a diverse resin portfolio and an intuitive Resin Selection Tool designed to streamline workflows and enhance production efficiency.

  3. Enhanced Chromatography Resins For Faster, More Efficient Purification 5/21/2025

    Learn from an industry veteran about the evolution of protein purification, from early equipment to modern, agile solutions, emphasizing continuous improvement and customer-centric approaches.

  4. Advancing Gene Therapy Development With A Multi-Serotype AAV Resin 5/29/2025

    In this webinar, leading CDMO ABL and Thermo Fisher will share data on implementation of the POROS™ CaptureSelect™ AAVX affinity resin into such an AAV purification platform, including its performance in purifying several serotypes.

  5. Scalable By Design: Streamlining Cell Culture Media Manufacturing 8/15/2024

    Learn ways to help improve quality, simplify technology transfer of proprietary media formulations, and mitigate logistical challenges associated with custom media scale-up processes.

  6. Dr. Peter Marks on the Adoption of Novel Precision Analytics 1/30/2024

    Hear advice for developers who are worried that the FDA will not accept changes in their process that include a new analytical method.

  7. Validation Of A qPCR Assay For Host Cell DNA Quantitation 6/9/2025

    Here, we share the development and validation of a new, highly sensitive and accurate integrated solution for detection and quantitation of host cell DNA to help meet regulatory requirements.

  8. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

  9. Supporting Efficacy And Scaling With A Next-Generation T Cell AOF Formulation Medium 6/16/2025

    Explore a novel, next-generation medium designed with an animal component-free formulation to boost therapeutic potential and enable reproducible T cells.

  10. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.